Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone.
The Pharma Data
SEPTEMBER 1, 2021
The FDA approval of INVEGA HAFYERA™ is based on the results of a 12-month, randomized, double-blind, non-inferiority Phase 3 global study that enrolled 702 adults (ages 18-70) living with schizophrenia from 20 countries. DFAPA, Medical Director at ATP Clinical Research and 6-month paliperidone palmitate clinical trial investigator.
Let's personalize your content